Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

IMV Inc IMVIF

Healthcare Biotechnology
IMV Inc. is a Canada-based company. The Company has no business operations.


GREY:IMVIF - Post by User

IMV Inc
Bullboard Posts
User Avatar Image
(77)
•••
Comment by GorgeousGeorge1on May 19, 2018 2:52pm
130 Views
Post# 28056770

RE:RE:RE:RE:Comments on IMV

RE:RE:RE:RE:Comments on IMVMore from Thom Calandra comments - June 3at theAmerican Society of Clinical Oncologistsmeeting in Chicago. This is the most widely attended scientific cancer conference of the year. 6,700 applicationsfor oral presentations for 100 slots this year. IMV is one of the 100 to present data from the Incyte ovarian cancer trial. The presenter will beOliver Dorigo, head of the ovarian cancer unit at Stanford University here in northern California Dr. Dorigospresentation please see abstract of his presentation on ASCO conference website you will recall the that IMV staged in midtown Manhattan a few weeks ago. Ive been working in this field of ovarian cancer for 25 years, and we have never seen anything like this kind of T-cell response. The ASCOabstract suggests 9 of 10 of those treated in alow-dose cohortshowed improvement.
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities